Article
Oncology
Yasuhiro Nagata, Shinichi Kageyama, Takeshi Ishikawa, Satoshi Kokura, Tetsuya Okayama, Tetsuya Abe, Masahiko Murakami, Koji Otsuka, Tomotake Ariyoshi, Takashi Kojima, Ken Taniguchi, Shinichiro Kobayashi, Hideaki Shimada, Satoshi Yajima, Takashi Suzuki, Satoshi Hirano, Takahiro Tsuchikawa, Toshiaki Shichinohe, Shugo Ueda, Kengo Kanetaka, Akira Yoneda, Hisashi Wada, Yuichiro Doki, Hiroki Yamaue, Masahiro Katsuda, Masaki Ohi, Hiromi Yasuda, Ken Kondo, Masato Kataoka, Yasuhiro Kodera, Masahiko Koike, Taizo Shiraishi, Yoshihiro Miyahara, Naoki Goshima, Eriko Fukuda, Kei Yamaguchi, Eiichi Sato, Hiroaki Ikeda, Tomomi Yamada, Masaharu Osako, Kaoru Hirai, Hiroshi Miyamoto, Takashi Watanabe, Hiroshi Shiku
Summary: The study aimed to determine the efficacy and biomarkers of the CHP-NY-ESO-1 vaccine in ESCC patients, revealing the vaccine's safety and potential prognostic factors.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Review
Immunology
Hong Zhou, Yipeng Ma, Fenglan Liu, Bin Li, Dongjuan Qiao, Peigen Ren, Mingjun Wang
Summary: NY-ESO-1 is a highly immunogenic tumor-associated antigen that is widely used in cancer immunotherapy. There are various types of NY-ESO-1-based cancer vaccines, each with its own advantages and obstacles, but they are of great significance for the treatment of solid cancers.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Takeshi Ishikawa, Shinichi Kageyama, Yoshihiro Miyahara, Tetsuya Okayama, Satoshi Kokura, Linan Wang, Eiichi Sato, Hideo Yagita, Yoshito Itoh, Hiroshi Shiku
Summary: The vaccine combining CHP-NY-ESO-1 and poly-ICLC showed good safety and immune response in a phase 1 clinical trial, with no observed tumor responses. All patients achieved antibody responses, with higher titers in the combination group.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Article
Immunology
Yusuf Dolen, Uzi Gileadi, Ji-Li Chen, Michael Valente, Jeroen H. A. Creemers, Eric A. W. Van Dinther, N. Koen van Riessen, Eliezer Jager, Martin Hruby, Vincenzo Cerundolo, Mustafa Diken, Carl G. Figdor, I. Jolanda M. de Vries
Summary: A PLGA-based nanoparticle vaccine containing immunogenic cancer germline antigen NY-ESO-1 and iNKT cell agonist was developed, which efficiently induced antigen-specific T cell responses in vivo without systemic toxicity at high doses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, General & Internal
Kazuhiko Hashimoto, Shunji Nishimura, Yu Shinyashiki, Tomohiko Ito, Ryosuke Kakinoki, Masao Akagi
Summary: This study aimed to determine the involvement of NY-ESO-1 and MAGE-A4 in desmoid tumors (DTs) and found that both might be involved in the DT microenvironment, suggesting that they may serve as diagnostic markers for DTs.
Article
Oncology
Sant P. Chawla, Brian A. Van Tine, Seth M. Pollack, Kristen N. Ganjoo, Anthony D. Elias, Richard F. Riedel, Steven Attia, Edwin Choy, Scott H. Okuno, Mark Agulnik, Margaret von Mehren, Michael B. Livingston, Vicki L. Keedy, Claire F. Verschraegen, Tony Philip, G. Chet Bohac, Sergey Yurasov, Adam Yakovich, Hailing Lu, Michael Chen, Robert G. Maki
Summary: This study investigated the efficacy and safety of combining the CMB305 regimen with atezolizumab compared to atezolizumab alone in patients with synovial sarcoma or myxoid liposarcoma. The combination therapy resulted in improved NY-ESO-1-specific T-cell and antibody responses, but did not significantly increase progression-free survival or overall survival compared to atezolizumab alone.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Xin Liu, Yixiang Xu, Wei Xiong, Bingnan Yin, Yuqian Huang, Junjun Chu, Changsheng Xing, Chen Qian, Yang Du, Tianhao Duan, Helen Y. Wang, Ningyan Zhang, John S. Yu, Zhiqiang An, Rongfu Wang
Summary: This study developed a TCR-like antibody and CAR-T cells to recognize intracellular proteins as a target for cancer immunotherapy. The specificity and antitumor activity of the antibody and CAR-T cells were demonstrated both in vitro and in vivo, providing a novel approach for the development of cancer immunotherapeutics.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Sandra N. Freiberger, David Holzmann, Gregoire B. Morand, Martin Huellner, Mitchell P. Levesque, Reinhard Dummer, Viktor H. Koelzer, Niels J. Rupp
Summary: This study investigates novel biomarkers in mucosal melanoma that predict response to combined ipilimumab and nivolumab immunotherapy. The results suggest that the testis antigens CTAG1B (NY-ESO-1), MAGE-A3, and MAGE-A4 are predominantly expressed in responding tumors, and could potentially be used for future routine diagnostics to predict treatment outcomes.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Alaa Alsalloum, Saleh Alrhmoun, Julia Shevchenko, Marina Fisher, Julia Philippova, Roman Perik-Zavodskii, Olga Perik-Zavodskaia, Julia Lopatnikova, Vasily Kurilin, Marina Volynets, Yasushi Akahori, Hiroshi Shiku, Alexander Silkov, Sergey Sennikov
Summary: This study investigates the specific targeting potential of engineered TCR T cells against NY-ESO-1-positive tumors. The cytotoxicity and functional characteristics of these modified T cells, as well as immune transcriptome profiling and multiplex immunoassays, demonstrate their promising therapeutic potential for cancer treatment.
Article
Biochemistry & Molecular Biology
Wenjie Gong, Lei Wang, Maria-Luisa Schubert, Christian Kleist, Brigitte Neuber, Sanmei Wang, Mingya Yang, Angela Huckelhoven-Krauss, Depei Wu, Anita Schmitt, Carsten Muller-Tidow, Hiroshi Shiku, Michael Schmitt, Leopold Sellner
Summary: This study investigated the potential of modulating the expression of the cancer-testis antigen NY-ESO-1 using histone deacetylase inhibitors (HDACis). The results showed that pretreatment with HDACi can enhance the cytotoxic efficacy of NY-ESO-1-specific T cells against NY-ESO-1-positive soft tissue sarcoma (STS) cells. Additionally, HDACis can enhance the immune reactivity of NY-ESO-1-specific T cells.
Article
Biochemical Research Methods
Hang Qu, Linyao Tan, Fang-cai Wu, Weiyuan Huang, Kaiwei Li, Xiaoyong Chen, Yi-wei Xu, Xuehao Hu
Summary: This study proposes a surface plasmonic tilted fiber Bragg grating biosensor for the detection of NY-ESO-1 antibody and investigation of the hook effect. The biosensor demonstrates a low limit of detection, good linearity, and repeatability.
BIOMEDICAL OPTICS EXPRESS
(2023)
Article
Oncology
Marion Grard, Mohamed Idjellidaine, Atousa Arbabian, Camille Chatelain, Laurine Berland, Chantal Combredet, Soizic Dutoit, Sophie Deshayes, Virginie Dehame, Nathalie Labarriere, Delphine Fradin, Nicolas Boisgerault, Christophe Blanquart, Frederic Tangy, Jean-Francois Fonteneau
Summary: Antitumor virotherapy uses oncolytic viruses to induce tumor cell lysis and stimulate the antitumor immune response. In this study, a modified measles virus expressing the cancer/testis antigen NY-ESO-1 showed similar oncolytic activity to the wild-type virus but induced faster cell lysis. The modified virus also successfully induced NY-ESO-1 expression and presentation in melanoma cells and dendritic cells, leading to the activation of NY-ESO-1-specific T cells.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Alexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, E. Andres Houseman, Shan Zhong, Jaegil Kim, Michael Nathenson, Thomas Faitg, Mary Woessner, David C. Turner, Aisha N. Hasan, John Glod, Rosandra N. Kaplan, Sandra P. D'Angelo, Dejka M. Araujo, Warren A. Chow, Mihaela Druta, George D. Demetri, Brian A. Van Tine, Stephan A. Grupp, Gregg D. Fine, Ioanna Eleftheriadou
Summary: This study identifies potential predictive and pharmacodynamic markers of response to NY-ESO-1 T-cell therapy in a solid tumor, which may inform lymphodepletion, cell dose, and strategies to enhance anticancer efficacy.
NATURE COMMUNICATIONS
(2022)
Article
Cell Biology
Qiuzhong Pan, Desheng Weng, Jiayong Liu, Zhaosheng Han, Yusheng Ou, Bushu Xu, Ruiqing Peng, Yi Que, Xizhi Wen, Jing Yang, Shi Zhong, Lun Zeng, Aiyuan Chen, Haiping Gong, Yanmei Lin, Jiewen Chen, Ke Ma, Johnson Y. N. Lau, Yi Li, Zhengfu Fan, Xing Zhang
Summary: The TAEST16001 cell therapy protocol is a safe and effective treatment for patients with NY-ESO-1-positive tumors. It involves dose-reduced lymphodepletion and the use of low doses of interleukin-2 to maintain TCR-T cells. Clinical trial results show a high response rate and improved progression-free survival for advanced soft tissue sarcoma patients.
CELL REPORTS MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Synat Kang, Lixin Wang, Lu Xu, Ruiqi Wang, Qingzheng Kang, Xuefeng Gao, Li Yu
Summary: Research shows that the combined use of NY-ESO-1-specific dTCR-T cells and DAC can effectively suppress the growth of leukemia cells and prolong the survival of AML patients.
Article
Oncology
Kenta Watanabe, Kuniaki Katsui, Soichiro Sugiyama, Kotaro Yoshio, Masahiro Kuroda, Takao Hiraki, Katsuyuki Kiura, Yoshinobu Maeda, Shinichi Toyooka, Susumu Kanazawa
Summary: This study retrospectively evaluated the clinical utility of SBRT in patients aged 80 years and older with early-stage NSCLC, showing that SBRT is feasible in this population, achieving good local control with minimal toxicity, and may be beneficial for elderly patients with early-stage NSCLC.
RADIATION ONCOLOGY
(2021)
Article
Oncology
Kiichiro Ninomiya, Toshihide Yokoyama, Katsuyuki Hotta, Isao Oze, Kuniaki Katsui, Tae Hata, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Shoichi Kuyama, Kenichiro Kudo, Toshiyuki Kozuki, Daijiro Harada, Masayuki Yasugi, Toshi Murakami, Masamoto Nakanishi, Nagio Takigawa, Yoshinobu Maeda, Katsuyuki Kiura
Summary: Despite no significant preventative effects of sodium alginate on radiation-induced esophagitis in NSCLC patients, early use of sodium alginate can reduce the incidence of CRT-induced febrile neutropenia.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Physiology
Akihiko Taniguchi, Naohiro Oda, Daisuke Morichika, Satoru Senoo, Junko Itano, Utako Fujii, Lili Guo, Ryota Sunami, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara
Summary: Neuropeptide Y (NPY) has protective effects against elastase-induced emphysema and targeting NPY may be a potential therapeutic strategy for delaying disease progression.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
(2022)
Article
Medicine, General & Internal
Eri Ando, Takamasa Nakasuka, Toshio Kubo, Akihiko Taniguchi, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masaomi Yamane, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
Summary: A 16-year-old boy with asthma developed infection after participating in recovery volunteer work following heavy rains in Japan. The infection was caused by a fungus called Aspergillus fumigatus. Despite treatment with voriconazole, his symptoms did not improve and he also developed allergic bronchopulmonary aspergillosis. Eventually, he underwent partial lung resection surgery to improve his symptoms.
Article
Oncology
Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Daijiro Harada, Yoshinobu Maeda, Katsuyuki Kiura
Summary: This study evaluated the safety of receiving SARS-CoV-2 vaccine in patients with advanced lung cancer receiving anticancer therapy. The results showed that anti-SARS-CoV-2 mRNA vaccination tends to be safe, but fever following vaccination tends to be more common among patients undergoing lung cancer treatment than among healthy individuals.
Article
Oncology
Eriko Miyawaki, Hirotsugu Kenmotsu, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
Summary: This study evaluated the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC following platinum-based chemoradiotherapy. The results showed that platinum-doublet chemotherapy significantly improved overall survival and may be a promising treatment for these patients.
Article
Oncology
Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, Shoichi Kuyama, Koji Inoue, Kenichi Gemba, Hirohisa Ichikawa, Yuka Kato, Naohiro Oda, Isao Oze, Tomoki Tamura, Toshiyuki Kozuki, Takahiro Umeno, Toshio Kubo, Katsuyuki Hotta, Akihiro Bessho, Yoshinobu Maeda, Katsuyuki Kiura
Summary: Pembrolizumab was effective for treating non-small-cell lung cancer patients with a poor performance status (PS) and programmed cell death ligand 1 (PD-L1) expression level of 50% or higher. However, the drug is not recommended for patients with a PS of 3 due to poor outcomes. Adverse events, including liver dysfunction, should be monitored closely.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Kenichiro Kudo, Kazuya Nishii, Go Makimoto, Nobuhisa Ishikawa, Yukari Tsubata, Masahiro Kodani, Nobukazu Fujimoto, Masahiro Yamasaki, Tetsuya Kubota, Nagio Takigawa, Kazunori Fujitaka, Nobuhiro Kanaji, Takuo Shibayama, Junko Itano, Chihiro Ando, Katsuyuki Hotta, Katsuyuki Kiura
Summary: Repeat rebiopsy may increase the ability to detect T790M mutation positivity rate in patients with T790M-negative non-small-cell lung cancer (NSCLC) detected by the first rebiopsy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Letter
Medicine, General & Internal
Katsuyuki Hotta, Etsuji Suzuki, Eiki Ichihara, Katsuyuki Kiura
JOURNAL OF INTERNAL MEDICINE
(2022)
Article
Oncology
Go Makimoto, Atsushi Shimonishi, Kadoaki Ohashi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
Summary: Tepotinib, a novel MET-tyrosine kinase inhibitor, has been shown to have antitumor effects in patients with MET-mutant non-small-cell lung cancer. The AmoyDx® panel, with its shorter turnaround time, has been launched in Japan as a companion test for tepotinib and has successfully diagnosed and treated patients.
CASE REPORTS IN ONCOLOGY
(2022)
Correction
Oncology
K. Hotta, S. Saeki, M. Yamaguchi, D. Harada, A. Bessho, K. Tanaka, K. Inoue, K. Gemba, M. Shiojiri, Y. Kato, T. Ninomiya, T. Kubo, J. Kishimoto, Y. Shioyama, K. Katsui, J. Sasaki, K. Kiura, K. Sugio
Article
Respiratory System
Masataka Taoka, Go Makimoto, Noriyuki Umakoshi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
Summary: A 76-year-old female with postoperative recurrent ALK-positive lung adenocarcinoma presenting with massive hemoptysis was effectively treated with bronchial artery embolization and Endobronchial Watanabe Spigot occlusion.
RESPIRATORY MEDICINE CASE REPORTS
(2022)
Article
Respiratory System
Go Makimoto, Mahito Misawa, Yoshinobu Maeda, Katsuyuki Kiura
Summary: Dasatinib is an effective medication for certain types of leukemia, but it can cause adverse events such as fluid retention. Chylothorax is a rare adverse reaction that typically occurs within 5 years of dasatinib initiation.
RESPIRATORY MEDICINE CASE REPORTS
(2022)
Article
Respiratory System
Hisao Higo, Kadoaki Ohashi, Shuta Tomida, Sachi Okawa, Hiromasa Yamamoto, Seiichiro Sugimoto, Satoru Senoo, Go Makimoto, Kiichiro Ninomiya, Takamasa Nakasuka, Kazuya Nishii, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Yoshinobu Maeda, Shinichi Toyooka, Katsuyuki Kiura
Summary: This study analyzed the expression of kinase-coding and cancer-related genes in idiopathic pulmonary fibrosis (IPF) using next-generation sequencing. The results revealed potential therapeutic targets for IPF, such as DCLK1 and STK33, and suggested personalized treatment options with PDK4, ERBB4, PIM2, and SYK. Further large-scale studies are needed to develop personalized therapies for IPF.
RESPIRATORY RESEARCH
(2022)
Article
Oncology
Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Daijiro Harada, Koji Inoue, Takuo Shibayama, Daizo Kishino, Shingo Harita, Nobuaki Ochi, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda, Katsuyuki Kiura
Summary: The study found that previous thoracic radiation therapy enhanced the efficacy of immune checkpoint inhibitor therapy in non-small-cell lung cancer patients, while extra-thoracic radiation therapy was associated with inferior outcomes.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2021)